Immunome (NASDAQ:IMNM) Shares Gap Up to $13.82

Immunome, Inc. (NASDAQ:IMNM - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $13.82, but opened at $14.26. Immunome shares last traded at $14.01, with a volume of 162,041 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IMNM. SVB Leerink began coverage on Immunome in a report on Monday, January 29th. They issued an "outperform" rating and a $30.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on Immunome in a report on Tuesday. They issued an "overweight" rating and a $24.00 price target on the stock. Wedbush boosted their target price on Immunome from $27.00 to $33.00 and gave the stock an "outperform" rating in a research note on Monday, April 1st. Leerink Partnrs restated an "outperform" rating on shares of Immunome in a research note on Monday, January 29th. Finally, Guggenheim began coverage on Immunome in a research report on Monday, April 15th. They set a "buy" rating and a $35.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $30.50.

Immunome Trading Up 1.7 %

The stock has a 50-day simple moving average of $21.76 and a 200 day simple moving average of $15.24. The company has a market cap of $839.24 million, a price-to-earnings ratio of -2.65 and a beta of 1.66.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.26). The company had revenue of $3.83 million during the quarter, compared to analyst estimates of $3.40 million. Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. As a group, research analysts forecast that Immunome, Inc. will post -1.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunome

Institutional investors and hedge funds have recently modified their holdings of the stock. Avidity Partners Management LP purchased a new position in shares of Immunome in the 4th quarter valued at about $14,268,000. TD Asset Management Inc purchased a new position in shares of Immunome in the 3rd quarter valued at about $1,063,000. Mayo Clinic purchased a new position in shares of Immunome in the 4th quarter valued at about $1,161,000. Cerity Partners LLC purchased a new position in shares of Immunome in the 4th quarter valued at about $656,000. Finally, Emfo LLC purchased a new position in shares of Immunome in the 4th quarter valued at about $633,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.